Agappe Diagnostics Ltd., a leading Indian manufacturer of In Vitro Diagnostics (IVD), has announced a strategic partnership with Japan-based Fujirebio Holdings Inc. to introduce India’s first “Make in India” In-Vitro Biomarkers utilizing CLEIA (Chemiluminescent Enzyme Immunoassay) technology. This collaboration marks a major milestone in India’s diagnostic sector, focusing on the early detection of critical diseases such as Alzheimer’s, cancer, and gastrointestinal disorders.
The CLEIA technology plays a crucial role in the field of IVD by enabling early disease detection, monitoring progression, and facilitating personalized treatments. Its use in oncology, for example, enhances the ability to detect cancer markers early, thereby improving patient survival rates, according to Thomas John, Managing Director of Agappe Diagnostics. Early detection of Alzheimer’s, in particular, offers the opportunity to slow the progression of the disease through medications and lifestyle interventions, potentially delaying its onset.
The partnership between Agappe Diagnostics and Fujirebio Holdings is a significant step forward for immunoassay technology in India. Through technology transfer and Contract Development and Manufacturing Organization (CDMO) agreements, the collaboration has already resulted in the launch of cartridge-based CLEIA systems, furthering India’s capabilities in advanced diagnostic tools. This initiative aligns with the “Make in Kerala for the Globe” mission, aimed at reducing dependency on imports, cutting costs, and promoting self-reliance in essential healthcare technologies.
In addition, Agappe Diagnostics has unveiled a new 1 lakh sq. ft. manufacturing facility at Infopark, Kakkanad, which will enhance its production capacity. This new unit complements its existing reagent facility in Pattimattom and its first equipment manufacturing unit located at Kinfra, Nellad.
